Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Company Overview - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance [3] - The company utilizes genetic insights to create therapies for both rare and more prevalent neurological disorders through its proprietary platforms, Cerebrum™ and Solidus™ [3] - Praxis has a diversified CNS portfolio that includes multiple programs across epilepsy and movement disorders, featuring four clinical-stage product candidates [3] Upcoming Event - Praxis will host a virtual investor event on May 2, 2025, from 10:00 a.m. to 11:30 a.m. EDT, focusing on its clinical programs in developmental and epileptic encephalopathies (DEEs) [1][2] - The event will be led by the Praxis management team, and a replay will be available for 90 days on the company's website [2] Clinical Studies - The company is conducting several studies, including: - The EMBOLD study evaluating relutrigine for SCN2A and SCN8A DEEs [4] - The EMERALD study evaluating relutrigine for broader DEEs [4] - The EMBRAVE3 study evaluating elsunersen for SCN2A gain-of-function DEE [4]